Emerging roles of the 26S Proteasome in nuclear hormone receptor-regulated transcription.
Summary of "Emerging roles of the 26S Proteasome in nuclear hormone receptor-regulated transcription."
The mechanisms by which Nuclear Hormone Receptors (NHRs) regulate transcription are highly dynamic and require interplay between a myriad of regulatory protein complexes including the 26S proteasome. Protein degradation is the most well-established role of the proteasome; however, an increasing body of evidence suggests that the 26S proteasome may regulate transcription in proteolytic and non-proteolytic mechanisms. Here we review how these mechanisms may apply to NHR-mediated transcriptional regulation.
This article was published in the following journal.
Name: Biochimica et biophysica acta
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/20728592
- DOI: http://dx.doi.org/10.1016/j.bbagrm.2010.08.005
Medical and Biotech [MESH] Definitions
Nuclear Receptor Coactivator 3
A nuclear receptor coactivator with specificity for ESTROGEN RECEPTORS and PROGESTERONE RECEPTORS. It contains a histone acetyltransferase activity that may play a role in CHROMATIN REMODELING during the process of nuclear receptor-induced transcription. The coactivator has been found at elevated levels in certain HORMONE-DEPENDENT NEOPLASMS such as those found in BREAST CANCER.
Nuclear Receptor Subfamily 1, Group D, Member 1
A DNA-binding orphan nuclear receptor that negatively regulates expression of ARNTL TRANSCRIPTION FACTORS and plays a role as a regulatory component of the circadian clock system. The Nr1d1 nuclear receptor expression is cyclically-regulated by a feedback loop involving its positive regulation by CLOCK PROTEIN; BMAL1 PROTEIN heterodimers and its negative regulation by CRYPTOCHROME and PERIOD PROTEINS.
Nuclear Receptor Subfamily 4, Group A, Member 3
An orphan nuclear receptor that is closely related to members of the thyroid-steroid receptor family. It was originally identified in NERVE CELLS, however it may play regulatory roles in a variety of other tissues.
Hepatocyte Nuclear Factors
Hepatocyte nuclear factors are a family of evolutionarily conserved transcription factors that are preferentially expressed in HEPATOCYTES. They play important roles in liver-specific transcription and are critical for CELL DIFFERENTIATION and METABOLISM.
Nuclear Receptor Co-repressor 2
A nuclear co-repressor protein that shows specificity for RETINOIC ACID RECEPTORS and THYROID HORMONE RECEPTORS. The dissociation of this co-repressor from nuclear receptors is generally ligand-dependent, but can also occur by way of its phosphorylation by members of the MAP KINASE SIGNALING SYSTEM. The protein contains two nuclear receptor interaction domains and four repressor domains and is closely-related in structure to NUCLEAR RECEPTOR CO-REPRESSOR 1.
We previously identified a gene, nuclear receptor-interaction protein (NRIP), which functions as a transcription cofactor in glucocorticoid receptor (GR) and human papillomavirus E2 (HPV E2)-driven ge...
Retinoid acid receptors are DNA-binding proteins mediating the biological effects of ligands through transcriptional activation. It is known that the activity of the 26S proteasome is important for nu...
Cumulative evidence indicates that the proteasome, which is mainly known as a protein-degrading machine, is very essential for gene expression. Destructive functions of the proteasome, i.e., ubiquitin...
The pituitary glycoprotein hormone follicle-stimulating hormone (FSH) is an integral component of the endocrine axis that regulates gonadal function and fertility. In order to transmit its signal, FSH...
Ligand-regulated nuclear receptors, such as estrogen receptors, glucocorticoid receptor, vitamin D receptor, and peroxisome proliferator-activated receptors, belong to the most widely studied and best...
Agents that increase HDL-C via reverse cholesterol transport could provide a new therapeutic option for the prevention of atherosclerotic cardiovascular disease. The investigators propose...
This study is for patients who have been treated with surgical removal of the testes or hormone therapy (Lupron or Zoladex) and whose prostate cancer has worsened despite this treatment....
Menopausal and postmenopausal women compose almost 20% of the Austrian population. Two thirds of all austrian women suffering from depression or anxiety disorders are over 45 years old. Th...
The investigators' proposed phase 2 clinical trial will be an open-label, non-randomized study among 80 women with metastatic breast cancer. The study treatment period will be up to twelve...
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet kn...